Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- PART I International Provision of Public Goods under a Globalized Intellectual Property Regime
- PART II Innovation and Technology Transfer in a Protectionist Environment
- PART III Sectoral Issues: Essential Medicines and Traditional Knowledge
- PART IV Reform and Regulation Issues
- 22 Issues Posed by a World Patent System
- 23 Intellectual Property Arbitrage: How Foreign Rules Can Affect Domestic Protections
- 24 An Agenda for Radical Intellectual Property Reform
- Comment: Whose Rules, Whose Needs? Balancing Public and Private Interests
- 25 Diffusion and Distribution: The Impacts on Poor Countries of Technological Enforcement within the Biotechnology Sector
- 26 Equitable Sharing of Benefits from Biodiversity-Based Innovation: Some Reflections under the Shadow of a Neem Tree
- 27 The Critical Role of Competition Law in Preserving Public Goods in Conflict with Intellectual Property Rights
- 28 Expansionist Intellectual Property Protection and Reductionist Competition Rules: A TRIPS Perspective
- 29 Can Antitrust Policy Protect the Global Commons from the Excesses of IPRs?
- Comment I: Competition Law as a Means of Containing Intellectual Property Rights
- 30 “Minimal” Standards for Patent-Related Antitrust Law under TRIPS
- Comment II: Competitive Baselines for Intellectual Property Systems
- 31 WTO Dispute Settlement: Of Sovereign Interests, Private Rights, and Public Goods
- 32 The Economics of International Trade Agreements and Dispute Settlement with Intellectual Property Rights
- 33 Intellectual Property Rights and Dispute Settlement in the World Trade Organization
- 34 WTO Dispute Resolution and the Preservation of the Public Domain of Science under International Law
- 35 Recognizing Public Goods in WTO Dispute Settlement: Who Participates? Who Decides? The Case of TRIPS and Pharmaceutical Patents Protection
- Index
35 - Recognizing Public Goods in WTO Dispute Settlement: Who Participates? Who Decides? The Case of TRIPS and Pharmaceutical Patents Protection
Published online by Cambridge University Press: 05 May 2010
- Frontmatter
- Contents
- List of contributors
- Preface
- PART I International Provision of Public Goods under a Globalized Intellectual Property Regime
- PART II Innovation and Technology Transfer in a Protectionist Environment
- PART III Sectoral Issues: Essential Medicines and Traditional Knowledge
- PART IV Reform and Regulation Issues
- 22 Issues Posed by a World Patent System
- 23 Intellectual Property Arbitrage: How Foreign Rules Can Affect Domestic Protections
- 24 An Agenda for Radical Intellectual Property Reform
- Comment: Whose Rules, Whose Needs? Balancing Public and Private Interests
- 25 Diffusion and Distribution: The Impacts on Poor Countries of Technological Enforcement within the Biotechnology Sector
- 26 Equitable Sharing of Benefits from Biodiversity-Based Innovation: Some Reflections under the Shadow of a Neem Tree
- 27 The Critical Role of Competition Law in Preserving Public Goods in Conflict with Intellectual Property Rights
- 28 Expansionist Intellectual Property Protection and Reductionist Competition Rules: A TRIPS Perspective
- 29 Can Antitrust Policy Protect the Global Commons from the Excesses of IPRs?
- Comment I: Competition Law as a Means of Containing Intellectual Property Rights
- 30 “Minimal” Standards for Patent-Related Antitrust Law under TRIPS
- Comment II: Competitive Baselines for Intellectual Property Systems
- 31 WTO Dispute Settlement: Of Sovereign Interests, Private Rights, and Public Goods
- 32 The Economics of International Trade Agreements and Dispute Settlement with Intellectual Property Rights
- 33 Intellectual Property Rights and Dispute Settlement in the World Trade Organization
- 34 WTO Dispute Resolution and the Preservation of the Public Domain of Science under International Law
- 35 Recognizing Public Goods in WTO Dispute Settlement: Who Participates? Who Decides? The Case of TRIPS and Pharmaceutical Patents Protection
- Index
Summary
ABSTRACT
The question of how to produce “global public goods” in a world of sovereign states with divergent norms and preferences, reflecting differences in economic development levels, increasingly confronts the international policy agenda. It raises issues not only for political decision-making but also for judicial interpretation of existing international agreements. This chapter analyzes this fundamental question in the context of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization (WTO), with particular emphasis on patent protection for pharmaceutical products. The TRIPS Agreement's provisions raise concerns over at least three public (or quasi-public) goods in this area: the generation of new knowledge, the provision of public health, and the maintenance of rules fostering open trade and competition. WTO judicial panels charged with resolving disputes regarding patents on medicines must determine, in interpreting ambiguous or conflicting legal texts, the extent to which they defer to national sovereignty, various multilateral processes, or their own interpretations of the appropriate balance among these objectives. Questions of “who participates” and “who decides” will be critical in this determination. The chapter notes structural weaknesses in the ability of developing countries to participate meaningfully in the WTO judicial process and offers suggestions for making their participation more meaningful so as to protect their interests.
Introduction
Policy analysts increasingly pose the question of how to produce “global public goods” in a world of sovereign states governing constituencies with divergent norms, preferences, and priorities that reflect gaping differences in levels of economic development.
- Type
- Chapter
- Information
- International Public Goods and Transfer of Technology Under a Globalized Intellectual Property Regime , pp. 884 - 908Publisher: Cambridge University PressPrint publication year: 2005
- 1
- Cited by